» Articles » PMID: 21050360

Low Pretreatment Total Testosterone (< 3 Ng/mL) Predicts Extraprostatic Disease in Prostatectomy Specimens from Patients with Preoperative Localized Prostate Cancer

Overview
Journal BJU Int
Specialty Urology
Date 2010 Nov 6
PMID 21050360
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: • To investigate the relationship between pretreatment testosterone levels and pathological specimen characteristics, by prospectively examining serum androgen concentrations in a well-studied cohort of patients who underwent radical prostatectomy (RP) for localized prostate cancer.

Patients And Methods: • A total of 107 patients with clinically localized prostate cancer had an assay of total testosterone before laparoscopic RP at our institution. • The results were classified into two groups based on the total serum testosterone: group1, < 3 ng/mL; group 2, ≥ 3 ng/mL. • Student's t-test was used to compare continuous variables, and Fisher's exact test or the chi-squared test was used to compare categorical variables. • Survival curves were established using the Kaplan-Meier method and compared using the log-rank test. In all tests, P < 0.05 was considered to indicate statistical significance.

Results: • All patients had localized prostate cancer based on digital rectal examination (DRE) and preoperative magnetic resonance imaging (MRI). Groups 1 and 2 were similar in terms of age, body mass index, preoperative co-morbidities (cardiovascular and diabetes mellitus), clinical stage of prostate cancer and preoperative PSA levels. • In pathological specimens, low total testosterone (< 3 ng/mL) was an independent risk factor for high Gleason score (> 7) and for locally advanced pathological stage (pT3 and pT4). • Higher preoperative testosterone correlated with disease confined to the gland. • There was no association between serum testosterone levels and surgical margin status, on the one hand, and biochemical recurrence on the other.

Conclusion: • Low serum testosterone appears to be predictive of aggressive disease (Gleason score >7 and extraprostatic disease, pathological stage > pT2) in patients who underwent RP for localized prostate cancer.

Citing Articles

Normal preoperative endogenous testosterone levels predict prostate cancer progression in elderly patients after radical prostatectomy.

Porcaro A, Panunzio A, Bianchi A, Cerrato C, Gallina S, Serafin E Ther Adv Urol. 2023; 15:17562872231154150.

PMID: 36846295 PMC: 9950604. DOI: 10.1177/17562872231154150.


Hypogonadism and urologic surgeries: a narrative review.

Fendereski K, Ghaed M, Calvert J, Hotaling J Transl Androl Urol. 2022; 11(7):1045-1062.

PMID: 35958902 PMC: 9360521. DOI: 10.21037/tau-22-308.


Narrative review of Mediterranean diet in Cilento: longevity and potential prevention for prostate cancer.

Ferro M, Lucarelli G, Buonerba C, Terracciano D, Boccia G, Cerullo G Ther Adv Urol. 2022; 13:17562872211026404.

PMID: 35173812 PMC: 8842148. DOI: 10.1177/17562872211026404.


Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review.

Manceau C, Fromont G, Beauval J, Barret E, Brureau L, Crehange G Cancers (Basel). 2021; 13(17).

PMID: 34503059 PMC: 8428218. DOI: 10.3390/cancers13174251.


Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Kourbanhoussen K, Joncas F, Wallis C, Hovington H, Dagenais F, Fradet Y Asian J Androl. 2021; 24(1):21-25.

PMID: 34259197 PMC: 8788605. DOI: 10.4103/aja.aja_58_21.